K
Keith M. Sullivan
Researcher at Duke University
Publications - 458
Citations - 40788
Keith M. Sullivan is an academic researcher from Duke University. The author has contributed to research in topics: Transplantation & Total body irradiation. The author has an hindex of 105, co-authored 447 publications receiving 39067 citations. Previous affiliations of Keith M. Sullivan include American Cancer Society & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Matched‐related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research
Julie A. Panepinto,Mark C. Walters,Jeanette Carreras,Judith C. W. Marsh,Christopher Bredeson,Robert Peter Gale,Gregory A. Hale,John T. Horan,Jill Hows,John P. Klein,Ricardo Pasquini,Irene Roberts,Keith M. Sullivan,Mary Eapen,Alina Ferster +14 more
TL;DR: This report confirms and extends earlier reports that HCT from HLA‐matched related donors offers a very high survival rate, with few transplant‐related complications and the elimination of sickle-related complications in the majority of patients who undergo this therapy.
Journal ArticleDOI
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.
Peter A. McSweeney,Richard A. Nash,Keith M. Sullivan,Jan Storek,Leslie J. Crofford,Roger Dansey,Maureen D. Mayes,Kevin T. McDonagh,J. Lee Nelson,Ted Gooley,Leona Holmberg,Chien-Shing Chen,Mark H. Wener,Katherine Ryan,Julie Sunderhaus,Ken Russell,John Rambharose,Rainer Storb,Daniel E. Furst +18 more
TL;DR: Though important treatment-related toxicities occurred after HDIT for SSc, modifications of initial approaches appear to reduce treatment risks, suggesting that HDIT is a promising new therapy for S sc that should be evaluated in prospective randomized studies.
Journal ArticleDOI
Pulmonary, Gonadal, and Central Nervous System Status after Bone Marrow Transplantation for Sickle Cell Disease
Mark C. Walters,Karen A. Hardy,Sandie Edwards,Thomas V. Adamkiewicz,James Barkovich,Françoise Bernaudin,George R. Buchanan,Nancy Bunin,Roswitha Dickerhoff,Roger Giller,Paul R. Haut,John T. Horan,Lewis L. Hsu,Naynesh Kamani,John E. Levine,David A. Margolis,Kwaku Ohene-Frempong,Melinda Patience,Rupa Redding-Lallinger,Irene Roberts,Zora R. Rogers,Jean E. Sanders,J. Paul Scott,Keith M. Sullivan +23 more
TL;DR: Individuals who had stable donor engraftment did not experience sickle-related complications after BMT, and were protected from progressive CNS and pulmonary disease, particularly among female recipients.
Journal ArticleDOI
Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation.
Keith M. Sullivan,Deeg Hj,Jean E. Sanders,A Klosterman,D Amos,Howard M. Shulman,George E. Sale,P.J. Martin,Robert P. Witherspoon,F R Appelbaum +9 more
TL;DR: It is concluded that deleting posttransplant immunosuppression is associated with frequent and severe hyperacute GVHD, infectious complications, and occasional poor graft function.
Journal ArticleDOI
Chronic graft-versus-host disease.
TL;DR: Standard treatment for severe chronic GVHD is a combination of cyclosporine and prednisone, an alternating day regimen of these two agents prolongs survival and reduces drug-related adverse events, and topical therapy to affected areas is preferred for patients with mild disease.